Difference between revisions of "Cladribine (Leustatin)"
Jump to navigation
Jump to search
(updated content) |
|||
| Line 11: | Line 11: | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
*[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
| + | *[[Marginal zone lymphoma]] | ||
| + | *[[Hairy cell leukemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 16:52, 20 June 2013
Also known as 2-chlorodeoxyadenosine, 2-CdA, Litak, or Movectro.
General information
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Marginal zone lymphoma
- Hairy cell leukemia
Patient drug information
- Cladribine (Leustatin) patient drug information (Chemocare)[3]
- Cladribine (Leustatin) patient drug information (UpToDate)[4]